Neurontin (Gabapentin)

Gabapentin binds to the α2δ subunit of voltage‑gated calcium channels in the central nervous system. This binding limits calcium entry into presynaptic neurons, reducing the release of excitatory neurotransmitters and thereby decreasing neuronal hyper‑excitability that contributes to seizures and pain.

The appropriate dose of Neurontin is individualized by the prescribing clinician based on the specific indication, patient age, renal function, and response to therapy. Dosage adjustments are made according to clinical guidelines and the patient’s tolerance.

Safety of gabapentin in pregnancy or while breastfeeding has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and discuss these considerations with the patient before initiating therapy.

To request Neurontin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with other anticonvulsants, gabapentin offers a distinct mechanism by targeting the α2δ calcium‑channel subunit, which can be advantageous for patients who do not respond to sodium‑channel blockers. It is generally well tolerated but may cause sedation and dizziness more frequently than some alternatives.

Neurontin should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keeping the product in a dry, controlled environment helps maintain its stability and potency.

Neurontin is taken orally, usually as tablets or capsules, with or without food. The exact administration schedule—once, twice, or three times daily—depends on the prescribed dose and the patient’s clinical response.

Serious risks include severe allergic reactions (such as rash or anaphylaxis), mood alterations including depression or suicidal thoughts, and respiratory depression, especially when combined with other central nervous system depressants or opioids. Prompt medical attention is required if any of these occur.

Neurontin is contraindicated in patients with known hypersensitivity to gabapentin or any of the tablet’s excipients. Caution is also advised for individuals with severe renal impairment, as dose adjustments are necessary, and for those taking other CNS depressants.